IntraCellular Therapies (ITCI)
(Delayed Data from NSDQ)
$72.37 USD
+0.37 (0.51%)
Updated Apr 19, 2024 04:00 PM ET
After-Market: $72.30 -0.07 (-0.10%) 7:58 PM ET
3-Hold of 5 3
D Value A Growth C Momentum C VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
ITCI 72.37 +0.37(0.51%)
Will ITCI be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for ITCI based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ITCI
Biotech Stock Roundup: REGN, SAGE, NMRA Down on Updates, ITCI Gains on Study Success
Intra-Cellular (ITCI) Up as Depression Drug Meets Study Goals
ITCI: What are Zacks experts saying now?
Zacks Private Portfolio Services
Intra-Cellular (ITCI) Moves 23.3% Higher: Will This Strength Last?
Intra-Cellular (ITCI) Q4 Loss Narrower Than Expected, Sales Miss
Biotech/Drug Stocks Q4 Earnings Due Feb 22: MRNA, BHC, NTLA, BMRN & More
Other News for ITCI
How Is The Market Feeling About Intra-Cellular Therapies?
Biotech Alert: Searches spiking for these stocks today
Biotech Alert: Searches spiking for these stocks today
Why Lantheus Holdings Inc's Stock Skyrocketed 11% in a Quarter
Analysts Are Bullish on Top Healthcare Stocks: Thermo Fisher (TMO), Intra-Cellular Therapies (ITCI)